Based in Gruenwald, Germany, Dermapharm Holding SE continues to solidify its position within the healthcare sector through a highly integrated business model. The company operates as a specialized player in the pharmaceutical industry, utilizing a comprehensive approach that spans the entire product lifecycle. This strategy encompasses in-house development, in-house production, and the strategic distribution of pharmaceuticals and various healthcare products designed for specifically targeted markets.
As of the market close on November 18, 2026, the company’s stock was trading at 33.45 EUR on the Xetra exchange. This current valuation reflects a period of significant movement over the past year; while the stock reached a 52-week high of 51.90 EUR in May 2026, it is currently trading near its 52-week low of 33.10 EUR. Despite this recent downward trend in share price, the company maintains a substantial market capitalization of 1.83 billion EUR.
The company’s financial metrics indicate a Price-to-Earnings (P/E) ratio of 13.59, providing a window into how the market is currently valuing its earnings relative to its stock price. Listed on the Frankfurt Stock Exchange, Dermapharm Holding SE remains a key entity in the German pharmaceutical landscape, leveraging its end-to-end capabilities to serve niche healthcare segments.




